News | Nuclear Imaging | January 27, 2016

UltraSPECT Marks 450th U.S. System Installation

UltraSPECT partners with HeartLight Pharmacy Services to help nuclear medicine facilities deliver reduced radiation dose, shortened scan time for patient, staff safety

UltraSPECT, 450th U.S. installation, Firelands Regional Medical Center, nuclear medicine, radiation safety

January 27, 2016 — UltraSPECT Inc. has marked the 450th U.S. installation of its low-dose image processing technology for nuclear medicine. The milestone was reached as Firelands Regional Medical Center, Sandusky, Ohio, acquired Xpress3.Cardiac imaging solution to reduce radiation exposure for patients and staff and meet the American Society of Nuclear Cardiology (ASNC) dose-reduction guidelines.

UltraSPECT’s installation at Firelands Regional Medical Center was part of the HeartSafe Imaging initiative introduced by Ohio-based radiopharmaceutical provider HeartLight Pharmacy Services; the initiative is designed to help nuclear medicine facilities reduce single-photon emission computed tomography (SPECT) radiation exposure and minimize scan time for patient comfort. HeartLight Pharmacy Services offers UltraSPECT products to nuclear medicine imaging facilities as part of its supply agreement.

“Partnering with UltraSPECT allowed us to help our customers deliver a low-dose, safer cardiac imaging solution,” said Laura Meyer, sales and marketing manager, HeartLight Pharmacy Services. “Firelands Regional Medical Center is now providing the reduced dose and reduced time cardiac scans, making the imaging service safer for both patients and staff, and that can be seen as a true differentiator in the marketplace.”

The Heart Center at Firelands Regional Medical Center offers a broad range of advanced cardiac services, including nuclear cardiology scans. It is also accredited in heart failure, is a certified chest pain center and is an American Heart Association Mission Lifeline heart attack receiving center.

"UltraSPECT has given us the ability to reduce radiation exposure to both staff and patients, while providing a superior image quality," said Chad Baldosser, lead nuclear medicine technologist at Firelands Regional Medical Center.

Xpress.Cardiac allows cardiac imaging to be performed at half-time or half-dose thanks to UltraSPECT’s reconstruction algorithms technology, Wide-Beam Reconstruction (WBR). The WBR image processing software for nuclear cardiac and oncology imaging addresses the clinical need for significant reduction in injection dose and shortened scan times, boosting patient safety, throughput and comfort without sacrificing image quality and diagnostic confidence at a fraction of the cost of a brand-new camera.

“Once customers implement one of UltraSPECT solutions, they really like the technology,” said Meyer. “Some of our customers had their radiation dosimetry badge readings go down, and one site improved by as much as 40 percent.”

For more information: www.ultraspect.com

Related Content

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

The FLASH Effect significantly improves the therapeutic ratio for curing cancer

News | Radiation Oncology | July 28, 2021
July 28, 2021 — IntraOp Medical Corporation announced that ...

Positrigo founders Max Ahnen, Ph.D. (left) and Jannis Fischer, Ph.D.

News | PET Imaging | July 16, 2021
According to ARRS’ American Journal of Roentgenology (AJR), reduced-dose CT depicts greater than 90% of lung nodules in children and young adults with cancer, identifying the presence of nodules with moderate sensitivity and high specificity.

Axial reformatted clinical (1.083 mSv) and reduced dose (0.318 mSv) CT images from a 17-year-old girl with osteosarcoma. A 2 mm left lower lobe nodule is clearly visible in the left lower lobe on the clinical CT image (arrow in A). The same nodule is vaguely apparent on the reduced-dose CT image (arrow in B), classified as present but poorly visible.

News | Computed Tomography (CT) | July 09, 2021
American Society for Radiation Oncology (ASTRO) to host in-person Annual Meeting in Chicago, October 24-27

Getty Images

News | ASTRO | July 08, 2021
July 8, 2021 — Registration opens today for the American Society for Radiation Oncology's (...
Aduhelm should be initiated in patients with mild cognitive impairment due to Alzheimer’s disease or mild Alzheimer’s dementia

Getty Images

News | PET Imaging | July 08, 2021
July 8, 2021 — Biogen and...
Studies conducted by Mass General Hospital and University of Virginia have concluded that PixelShine, a disruptive technology from AlgoMedica, significantly improved the diagnostic quality of CT scans acquired at reduced radiation dose. Here, you can see before and after noise reduction is applied.

Studies conducted by Mass General Hospital and University of Virginia have concluded that PixelShine, a disruptive technology from AlgoMedica, significantly improved the diagnostic quality of CT scans acquired at reduced radiation dose. Here, you can see before and after noise reduction is applied.

Feature | Computed Tomography (CT) | July 02, 2021 | By Mikael Strindlund
The U.S. Food and Drug Administration (FDA) approved a new imaging agent for detection of prostate cancer, providing a more effective imaging approach to detect the spread of cancer to other parts of the body. Piflufolastat F-18 injection is the first fluorinated prostate-specific membrane antigen (PSMA) agent approved by the FDA and also the first commercially available PSMA PET imaging agent.

Image courtesy of JNM

News | PET Imaging | June 28, 2021
June 28, 2021 — The U.S.
Master Supply Agreement encompasses clinical development and commercial supply for Clarity’s Cu-67-based candidates to treat neuroblastoma, breast and prostate cancers, among others
News | Radiopharmaceuticals and Tracers | June 22, 2021
June 22, 2021 — NorthStar Medical Radioisotopes, LLC, a global innovator in the development, production and commercia
A novel positron emission tomography (PET) radiotracer has been shown to effectively measure increases in brain tau—a distinguishing characteristic of Alzheimer’s disease—before any symptoms of the disease are observed.

Figure 1. Tau accumulation over one year measured in composite A) mesial temporal ROI; and B) temporoparietal ROI in cognitively unimpaired participants (blue) and cognitively impaired participants (red). The CI group included participants with clinical mild cognitive impairment and dementia. Higher rates of tau accumulation were observed in participants on the AD continuum (CU Aβ+ve and CI Aβ+ve). Participants with the highest baseline tau and rates of tau accumulation were younger and more likely to be CI Aβ+ve. Image courtesy of SNMMI

News | PET Imaging | June 16, 2021
June 16, 2021 — A novel positron emission tomography (PET